A Phase 1, Open-label Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Pharmacokinetics and Safety of BMS-986235
Latest Information Update: 28 Mar 2022
At a glance
- Drugs BMS 986235 (Primary) ; Bupropion; Fluconazole; Itraconazole
- Indications Heart failure; Inflammation
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 10 Mar 2022 Planned primary completion date changed from 8 Jun 2021 to 7 Jun 2021.
- 10 Mar 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 16 Jul 2020 New trial record